Clinical Trial Update: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating orteronel (TAK-700) in combination with hormone therapy and radiation therapy for high-risk prostate cancer has completed and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Orteronel (TAK-700) (Orteronel)

Snippet

Sponsor: Radiation Therapy Oncology Group | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-04-18